# Ondansetron Orally Disintegrating Tablets

Notice 44e2d74f5e1341d4a4a0d45efbb3a79d (solicitation SPE2D2-25-R-0018) from DEPT OF DEFENSE, DLA TROOP SUPPORT, posted 2025-08-07, responses due -. Status: open.

| Field | Value |
| --- | --- |
| Notice ID | 44e2d74f5e1341d4a4a0d45efbb3a79d |
| Solicitation number | SPE2D2-25-R-0018 |
| Type | Presolicitation |
| Agency | DEPT OF DEFENSE |
| Sub-tier | DEFENSE LOGISTICS AGENCY |
| Office | DLA TROOP SUPPORT |
| Posted | 2025-08-07T19:48:13.000Z |
| Response deadline (UTC) | - |
| Set-aside | - |
| NAICS | 325412 |
| PSC | 6505 |
| Place of performance | - |
| Award | - |

## Description

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT). Procurement details follow. Ondansetron ODT 4 MG Tablet in 30 count bottles. Ondansetron ODT 8 MG Tablet in 10 and 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Nancy Fernandez at (445) 737-0713, (Nancy.Fernandez@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is September of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date. *The Ondansetron HCL Tablets will be solicited in a separate acquisition.

## Sources

- View on SAM.gov: https://sam.gov/opp/44e2d74f5e1341d4a4a0d45efbb3a79d/view
- Data as of 2026-11-14. Source: https://sam.gov/data-services/Contract%20Opportunities/datagov

## Cite this

"Ondansetron Orally Disintegrating Tablets, SAM.gov contract opportunity 44e2d74f5e1341d4a4a0d45efbb3a79d." samgovapi.io, https://samgovapi.io/opportunity/44e2d74f5e1341d4a4a0d45efbb3a79d, data as of 2026-11-14. Primary record: https://sam.gov/opp/44e2d74f5e1341d4a4a0d45efbb3a79d/view

## API and MCP

- REST: GET https://samgovapi.io/api/v1/opportunities/44e2d74f5e1341d4a4a0d45efbb3a79d
- MCP tool: get_opportunity

Independent. Not affiliated with, endorsed by or sponsored by GSA, SAM.gov or any U.S. government agency. Registering in SAM.gov is free at sam.gov.

Get a free API key: https://samgovapi.io/sign-up?ref=ai-claudebot